By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Consort Medical, a UK-based manufacturer of drug delivery and medical device technologies, has acquired a roughly 20 percent stake in Atlas Genetics for £1.1 million ($1.8 million).

The firms also announced an alliance, under which Consort's Bespak division will design disposable test cards that will be part of Atlas' rapid, point-of-care molecular diagnostics system. Consort said that it also has received long-term manufacturing rights for the cards.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.